Non‐alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non‐diabetic men. Role of visceral adipose tissue
- 13 September 2005
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 22 (10) , 1354-1358
- https://doi.org/10.1111/j.1464-5491.2005.01646.x
Abstract
Aims To compare plasma biomarkers of inflammation and endothelial dysfunction in individuals with and without non‐alcoholic hepatic steatosis (HS), and to evaluate whether such differences were mediated by the adverse metabolic pattern, typically found in these subjects. Methods HS (by ultrasound and computed tomography), visceral fat (by computed tomography), insulin resistance (by homeostasis model assessment—HOMA), plasma biomarkers of inflammation and endothelial dysfunction (hs‐C reactive protein, fibrinogen, von Willebrand factor, plasminogen activator inhibitor‐1 activity) were measured in 100 non‐smoking, healthy, male volunteers. Results Plasma hs‐CRP, fibrinogen, v‐WF and plasminogen activator inhibitor‐1 (PAI‐1) activity levels were markedly higher (P < 0.01 or less) in subjects with non‐alcoholic HS (n = 35) than in those without HS (n = 65). The former also had significantly higher values for body mass index (BMI), visceral fat, diastolic blood pressure, HOMA insulin resistance score, plasma insulin (both fasting and after glucose load), triglycerides, liver enzymes, and lower high‐density lipoprotein (HDL)‐cholesterol concentration. While the marked differences in these pro‐inflammatory biomarkers observed between the groups were little affected by adjustment for age, BMI, blood pressure values, HOMA insulin resistance score, plasma triglyceride and liver enzyme concentrations, they were completely abolished after controlling for visceral fat. Similarly, in multivariate regression analyses, increased visceral fat significantly predicted the pro‐inflammatory biomarkers, independently of HS and other potential confounders. Conclusions These results indicate that, in non‐smoking, non‐diabetic men, the significant increase of plasma biomarkers of inflammation and endothelial dysfunction in the presence of non‐alcoholic HS is largely mediated by abdominal visceral fat accumulation.Keywords
This publication has 23 references indexed in Scilit:
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡Hepatology, 2004
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand RosiglitazoneHepatology, 2003
- Cytokines and Nash: A Pilot Study of the Effects of Lifestyle Modification and Vitamin EHepatology, 2003
- Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitisJournal of Hepatology, 2003
- Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese WomenJAMA, 2003
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver DiseaseDrugs, 2003
- Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2002
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care, 2000
- Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy MenArteriosclerosis, Thrombosis, and Vascular Biology, 1996